Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
ViewRay, Inc. logo — Conquer cancer by re-envisioning radiation therapy.

ViewRay, Inc.

Conquer cancer by re-envisioning radiation therapy.

Founded 2004 United States United States 76 employees Post-IPO Debt Total: $462.49M Biotechnology, Health Care +2

General Information

Company Name ViewRay, Inc.
Founded Year 2004
Location United States United States
Founders / Decision Makers
Team member Team member Team member
Employees 76
Industries Biotechnology, Health Care, Manufacturing +1
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with ViewRay, Inc.. To contact ViewRay, Inc., visit viewray.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ViewRay, Inc. compare?

A PDF of ViewRay, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ViewRay, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ViewRay, Inc.

ViewRay, Inc. is a pioneering company, founded in 2004, with a mission to revolutionize cancer treatment. Its flagship product, the MRIdian® MRI-guided adaptive radiotherapy system, is disrupting the field with its innovative approach. The system's real-time imaging capability, precise dose shaping, and automated beam gating set it apart from existing radiation therapy technologies. With over $125.00MPost-IPO Debt investment from MidCap Financial and Silicon Valley Bank in November 2022, ViewRay, Inc. is poised for further growth. The company's dedication to advancements in biotechnology, healthcare, and manufacturing make it an attractive prospect for investors looking to make a meaningful impact in the fight against cancer. ViewRay, Inc.'s commitment to diversity and its focus on improving patient outcomes position it as an innovative and purpose-driven player in the industry. With a track record of treating over 12,500 patients worldwide, ViewRay, Inc. is demonstrating tangible results and offering a compelling opportunity for stakeholders seeking to make a difference in cancer care.

Business keywords: Radiation Therapy, Cancer Treatment, MRI-guided Adaptive Radiotherapy, Medical Technology, Oncology, MRI Technology, Healthcare Innovation, Clinical Imaging, Cancer Therapy, Precision Medicine, Radiation Oncology, Cancer Care, Tumor Targeting, Patient Outcomes

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $80.50M -
19 Nov 2021
Post IPO Equity $36.00M 1
Elekta
06 Dec 2019
Debt Financing $56.00M 1
Armentum Partners
Armentum Partners
01 Jan 2019
Post IPO Equity $59.00M -
26 Feb 2018
Post IPO Equity $50.00M -
25 Oct 2017
Post IPO Equity $14.00M 3
OrbiMed Xeraya Capital Kearny Venture Partners
OrbiMed, Xeraya Capital +1
22 Aug 2016
Post IPO Equity $2.72M -
28 Aug 2015
Post IPO Debt $50.00M 1
CRG
CRG
30 Jun 2015
Venture Round $15.00M -
04 Mar 2015
Series C $16.27M -
09 Jan 2015

View All 15 Funding Rounds

ViewRay, Inc. Alternatives & Competitors

View All Alternatives
ViewRay, Inc. vs
Cvergenx
Cvergenx United States

An innovative leader in cancer molecular diagnostics, delivering personalized radiation therapy to e...

Seed
2 employees
Biotechnology, Health Care
Compare ViewRay, Inc. vs Cvergenx
ViewRay, Inc. vs
Mevion Medical Systems
Mevion Medical Systems United States

Proton Therapy Has Changed. Right Size. Right Technology. Right Now.

Private Equity
202 employees
Biotechnology, Health Care
Compare ViewRay, Inc. vs Mevion Medical Systems
ViewRay, Inc. vs
IBA Dosimetry
IBA Dosimetry Germany

Treat more Patients Safely

193 employees
Health Care, Manufacturing
Also compare with: ViewRay, Inc. vs BioProtect Ltd BioProtect Ltd ViewRay, Inc. vs MVision AI MVision AI View all alternatives

FAQ About ViewRay, Inc.

Conquer cancer by re-envisioning radiation therapy.
ViewRay, Inc. was founded in 2004.
ViewRay, Inc. is headquartered in United States.
ViewRay, Inc. operates in Biotechnology, Health Care, Manufacturing and Medical Devices. Its work centres on Radiation Therapy, Cancer Treatment, MRI-guided Adaptive Radiotherapy and Medical Technology.
ViewRay, Inc. has approximately 76 employees.
ViewRay, Inc. has completed 15 funding rounds, raising a total of $462.49M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to ViewRay, Inc. include Cvergenx, Mevion Medical Systems, IBA Dosimetry, MagnetTx Oncology Solutions Ltd, RTsafe. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ViewRay, Inc. and Cvergenx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ViewRay, Inc., https://bouncewatch.com/company/viewray-inc, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes